成都先导(688222) - 2020 Q1 - 季度财报

Important Notice Management Statement The company's management guarantees the truthfulness and completeness of this unaudited quarterly report, assuming full legal responsibility - The company's management guarantees the truthfulness, accuracy, and completeness of this quarterly report[5] - This company's Q1 2020 report is unaudited[5] Company Profile Key Financial Data Q1 2020 saw significant declines in revenue and net profit, with operating cash flow turning negative, despite an increase in R&D investment as a percentage of revenue Key Financial Indicators for Q1 2020 | Indicator | Current Reporting Period | Prior Year Period | Year-on-Year Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue (Yuan) | 44,112,298.63 | 50,753,027.36 | -13.08% | | Net Profit Attributable to Listed Company Shareholders (Yuan) | 8,740,267.66 | 44,423,346.20 | -80.33% | | Net Profit Attributable to Listed Company Shareholders (Excluding Non-recurring Items) (Yuan) | 7,322,862.37 | 8,661,384.83 | -15.45% | | Net Cash Flow from Operating Activities (Yuan) | -1,897,162.63 | 44,898,574.81 | -104.23% | | Basic Earnings Per Share (Yuan/Share) | 0.02 | 0.12 | -80.33% | | Weighted Average Return on Net Assets (%) | 1.69% | 10.79% | Decreased by 9.10 percentage points | | R&D Investment as % of Operating Revenue (%) | 50.72% | 37.16% | Increased by 13.56 percentage points | - Total non-recurring gains and losses for the period amounted to 1.42 million yuan, primarily comprising 1.64 million yuan in government subsidies[8][9] Shareholder Holdings As of the reporting period end, the company had 13 shareholders, with the top ten holding significant restricted stakes, led by JIN LI (Li Jin) - As of the end of the reporting period, the company had 13 shareholders[11] Top Five Shareholder Holdings | Shareholder Name | Number of Shares Held (Shares) | Proportion (%) | | :--- | :--- | :--- | | JIN LI (Li Jin) | 81,876,948 | 22.744 | | Lhasa Economic and Technological Development Zone Huabo Medical Devices Co., Ltd. | 59,153,274 | 16.431 | | Chengdu Juzhi Kechuang Biotechnology Partnership (Limited Partnership) | 38,651,163 | 10.737 | | Lhasa Economic and Technological Development Zone Dongfang Jiayu Investment Partnership (Limited Partnership) | 37,667,721 | 10.463 | | Shenzhen Juntian Investment Enterprise (Limited Partnership) | 24,059,859 | 6.683 | - Shareholder JIN LI (Li Jin) and Chengdu Juzhi Kechuang Biotechnology Partnership (Limited Partnership) are parties acting in concert[13] Significant Events Analysis of Significant Changes in Key Financial Items Significant changes in financial items include increased receivables and inventory, negative finance expenses due to exchange rates, sharp declines in other income and sales expenses, and a 104% drop in operating cash flow Changes and Reasons for Key Accounting Items | Item | Change (%) | Reason for Change | | :--- | :--- | :--- | | Balance Sheet | | | | Other Receivables | 67% | Primarily due to IPO issuance expenses advanced by the company using its own funds | | Inventory | 41% | Primarily due to increased raw material procurement | | Income Statement | | | | Selling Expenses | -31% | Primarily due to decreased market expansion and legal service fees caused by the global pandemic | | Finance Expenses | -260% | Primarily due to fluctuations in the RMB to USD exchange rate | | Other Income | -96% | Primarily due to the absence of significant one-time operating-related government subsidies in this period | | Cash Flow Statement | | | | Net Cash Flow from Operating Activities | -104% | Primarily due to the absence of significant one-time operating-related government subsidies and increased raw material procurement in this period | Progress of Significant Events The company had no significant events requiring disclosure during the reporting period - Not applicable[14] Performance Forecast and Warning The company has not issued any performance forecasts or warnings regarding cumulative net profit - Not applicable[15] Appendix Financial Statements This section presents the company's unaudited consolidated and parent company financial statements for Q1 2020, serving as the source for all reported financial data Consolidated Balance Sheet As of March 31, 2020, total assets were 634.17 million yuan, total liabilities 113.08 million yuan, and parent company equity 521.09 million yuan Key Items from Consolidated Balance Sheet (March 31, 2020) | Item | Amount (Yuan) | | :--- | :--- | | Total Assets | 634,167,874.02 | | Total Liabilities | 113,076,032.51 | | Total Equity Attributable to Parent Company Owners | 521,091,841.51 | Consolidated Income Statement Q1 2020 saw total operating revenue of 44.11 million yuan, with R&D expenses exceeding 50% of revenue, leading to a net profit of 8.74 million yuan Key Items from Consolidated Income Statement (Q1 2020) | Item | Amount (Yuan) | | :--- | :--- | | Total Operating Revenue | 44,112,298.63 | | Total Operating Costs | 34,858,761.09 | | Including: R&D Expenses | 22,375,778.77 | | Total Profit | 10,921,073.17 | | Net Profit | 8,740,267.66 | Consolidated Cash Flow Statement Q1 2020 operating cash flow was -1.90 million yuan, with significant outflows from investing and financing activities, and period-end cash balance of 297.10 million yuan Key Items from Consolidated Cash Flow Statement (Q1 2020) | Item | Amount (Yuan) | | :--- | :--- | | Net Cash Flow from Operating Activities | -1,897,162.63 | | Net Cash Flow from Investing Activities | -33,424,459.92 | | Net Cash Flow from Financing Activities | -5,224,241.78 | | Cash and Cash Equivalents at Period End | 297,098,724.92 | Changes and Adjustments to Accounting Standards The company adopted new revenue recognition standards from January 1, 2020, reclassifying certain balance sheet items without impacting net assets or net profit - The company adopted new revenue recognition standards from January 1, 2020, adjusting financial statement items at the beginning of 2020 based on cumulative impact, without adjusting comparable period data[36][41] Key Consolidated Balance Sheet Adjustment Items (January 1, 2020) | Item | Before Adjustment (Yuan) | Adjustment Amount (Yuan) | After Adjustment (Yuan) | | :--- | :--- | :--- | :--- | | Accounts Receivable | 33,108,079.00 | -5,658,736.70 | 27,449,342.30 | | Contract Assets | 0 | 5,658,736.70 | 5,658,736.70 | | Prepayments | 35,269,606.50 | -35,269,606.50 | 0 | | Contract Liabilities | 0 | 35,269,606.50 | 35,269,606.50 |